Keytruda (pembrolizumab)

pCPA File Number: 22073
Negotiation Status:
Under consideration for negotiation
Indication(s):
for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable